A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.

Ira GantzMenghui ChenShailaja SuryawanshiCatherine NtabaddeSukrut ShahEdward A O'NeillSamuel S EngelKeith D KaufmanEseng Lai

Published in: Cardiovascular diabetology (2017)

In this CV safety study of patients with T2DM and established CV disease, omarigliptin did not increase the risk of MACE or hHF and was generally well tolerated. Trial registration ClinicalTrials.gov: NCT01703208. Registered 05 October 2012.

Keyphrases

study protocol
phase iii
double blind
metabolic syndrome
adipose tissue